Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 114,600 shares, a growth of 165.9% from the February 28th total of 43,100 shares. Approximately 0.0% of the company's stock are short sold. Based on an average daily volume of 331,200 shares, the short-interest ratio is currently 0.3 days.

Chugai Pharmaceutical Stock Down 0.5 %

CHGCY stock traded down $0.12 during trading on Monday, hitting $23.09. 69,510 shares of the company's stock traded hands, compared to its average volume of 196,065. The business has a fifty day simple moving average of $23.16 and a two-hundred day simple moving average of $22.90. The firm has a market capitalization of $75.99 billion, a P/E ratio of 29.99 and a beta of 0.77. Chugai Pharmaceutical has a 1 year low of $14.52 and a 1 year high of $27.19.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.18 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. On average, equities research analysts predict that Chugai Pharmaceutical will post 0.74 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.